Tablas de Dosis Calculadora Mezclas & Stacks Aprender Blog Péptidos Aprobaciones
Abrir Calculadora
PeptideDosageCharts  ›  Aprobaciones

Evidencia y Estado de Aprobación

Todos los péptidos que cubrimos, clasificados por la evidencia real — desde medicamentos aprobados por reguladores (FDA, EMA, MHRA, TGA) hasta compuestos en fase clínica y preclínica. Verificado con reguladores y la literatura revisada por pares.

Compuesto Categoría Nivel de evidencia Aprobado por Base / marca
Tesamorelin Egrifta Growth Hormone Aprobado FDA Egrifta — FDA 2010, HIV-associated lipodystrophy
HCG Human Chorionic Gonadotropin Hormonal Aprobado FDA EMA Pregnyl/Novarel/Ovidrel — FDA, fertility & hypogonadism
Oxytocin Hormonal Aprobado FDA EMA MHRA TGA Pitocin/Syntocinon — FDA, labor induction & PPH
SS-31 Elamipretide Mitochondrial Aprobado FDA Forzinity (elamipretide) — FDA Sep 2025, Barth syndrome
HGH 191AA Somatropin Growth Hormone Aprobado FDA EMA MHRA TGA Somatropin (Genotropin/Norditropin) — FDA/EMA, GH deficiency
Tirzepatide Mounjaro / LY3298176 GLP-1 / Metabolic Aprobado FDA EMA MHRA TGA Mounjaro/Zepbound — FDA 2022, T2D, obesity & OSA
Gonadorelin GnRH Hormonal Aprobado FDA Factrel — FDA, GnRH for pituitary testing (discontinued)
Sermorelin Growth Hormone Aprobado FDA Geref — FDA 1997 (discontinued 2008), pediatric GH deficiency
Melanotan I Afamelanotide Other Aprobado FDA EMA TGA Scenesse (afamelanotide) — FDA 2019/EMA 2015, erythropoietic protoporphyria
PT-141 Bremelanotide Other Aprobado FDA Vyleesi (bremelanotide) — FDA 2019, HSDD
Semaglutide Ozempic / Wegovy GLP-1 / Metabolic Aprobado FDA EMA MHRA TGA Ozempic/Wegovy/Rybelsus — FDA 2017, diabetes & obesity
GHRP-2 Growth Hormone Aprobado PMDA Pralmorelin (GHRP Kaken) — PMDA Japan, GH-deficiency diagnostic
Liraglutide Victoza / Saxenda GLP-1 / Metabolic Aprobado FDA EMA MHRA TGA Victoza/Saxenda — FDA/EMA, T2D & obesity
VIP Vasoactive Intestinal Peptide Other Aprobado MHRA As Invicorp (VIP+phentolamine) — MHRA UK 2000, erectile dysfunction
Dulaglutide Trulicity GLP-1 / Metabolic Aprobado FDA EMA Trulicity — FDA & EMA 2014, type 2 diabetes
Pentosan Polysulfate PPS Healing & Recovery Aprobado FDA EMA TGA Elmiron — FDA 1996, interstitial cystitis
Orforglipron LY3502970 GLP-1 / Metabolic Aprobado FDA Foundayo — FDA Apr 2026, oral GLP-1 for chronic weight management
Tirzepatide 15mg Mounjaro GLP-1 / Metabolic Aprobado FDA EMA MHRA TGA Mounjaro 15mg — FDA/EMA, highest maintenance dose
Amlexanox Metabolic Aprobado FDA Aphthasol — FDA 1997, aphthous ulcers (US-discontinued)
Exenatide Byetta / Bydureon GLP-1 / Metabolic Aprobado FDA EMA Byetta/Bydureon — FDA 2005, type 2 diabetes
Pramlintide Symlin GLP-1 / Metabolic Aprobado FDA Symlin — FDA 2005, amylin analog adjunct to insulin
IGF-1 (IGtropin) IGF-1 Growth Factor Aprobado FDA EMA As Mecasermin (Increlex) — FDA/EMA, severe primary IGF-1 deficiency
Setmelanotide Imcivree Metabolic Aprobado FDA EMA Imcivree — FDA 2020/EMA, monogenic & hypothalamic obesity
Lixisenatide Adlyxin GLP-1 / Metabolic Aprobado FDA EMA TGA Adlyxin/Lyxumia — FDA/EMA, type 2 diabetes
ACTH 1-39 Corticotropin, full-length ACTH Hormonal Aprobado FDA as corticotropin (H.P. Acthar Gel)
Triptorelin Triptorelin Acetate, Trelstar, Decapeptyl Hormonal Aprobado FDA EMA GnRH agonist (Trelstar/Decapeptyl)
Noopept Cognitive Aprobado (intl) ROSZ Russia (ROSZ) — vascular/traumatic cognitive disorders
Cerebrolysin Cognitive Aprobado (intl) INTL National approval Austria (EU) + 50+ countries; not FDA/EMA-central
Selank Cognitive Aprobado (intl) ROSZ Russia (ROSZ) — prescription anxiolytic
Semax Cognitive Aprobado (intl) ROSZ Russia (ROSZ) — ischemic stroke & cognitive disorders
Thymosin Alpha-1 Zadaxin Immune Aprobado (intl) NMPA Zadaxin — Italy (EU) + China + 35 countries; not FDA/EMA-central
Mazdutide IBI362 / LY3305677 GLP-1 / Metabolic Aprobado (intl) NMPA China NMPA 2025 — GCG/GLP-1 agonist for obesity & T2D
Thymalin Immune Aprobado (intl) ROSZ Russia (ROSZ) since 1982 — immunomodulator
Thymogen Glutamyl-Tryptophan Immune Aprobado (intl) ROSZ Russia (ROSZ) — Glu-Trp immunostimulant
BPC-157 Body Protection Compound 157 Healing & Recovery Evidencia clínica No aprobado Small pilot human studies exist; unapproved, FDA Category 2 (barred from compounding).
GHK-Cu Copper Peptide Skin & Repair Evidencia clínica No aprobado Human topical skin/wound/hair studies; cosmetic ingredient, not an approved drug.
Glutathione GSH Longevity Evidencia clínica No aprobado Antioxidant sold as a supplement; human IV/oral trials exist, no drug approval as GSH.
NAD+ Nicotinamide adenine dinucleotide Longevity Evidencia clínica No aprobado Endogenous coenzyme sold as a supplement; human trials exist, not a drug.
NMN Nicotinamide Mononucleotide Longevity Evidencia clínica No aprobado Dietary supplement (FDA: not a drug) with multiple human RCTs on NAD+ raising.
MK-677 Ibutamoren Growth Hormone Evidencia clínica No aprobado Oral GH secretagogue completed multiple Phase 2/3 trials; never submitted/approved.
Retatrutide LY3437943 GLP-1 / Metabolic Evidencia clínica No aprobado Investigational triple agonist in Phase 3 obesity trials; not yet approved.
Spermidine Longevity Evidencia clínica No aprobado Dietary polyamine with human RCTs (mixed); sold as a supplement, not a drug.
Melanotan II MT-II Other Evidencia clínica No aprobado Unapproved melanocortin agonist with small human trials; precursor to bremelanotide.
Ipamorelin Growth Hormone Evidencia clínica No aprobado Selective GH secretagogue reached early-phase human trials; never approved.
SNAP-8 Skin & Repair Evidencia clínica No aprobado Topical cosmetic octapeptide with human in-vivo wrinkle studies; not a drug.
AOD-9604 Metabolic Evidencia clínica No aprobado Multiple human obesity trials (Phase 2b) that failed efficacy; food-ingredient GRAS only.
Argireline Acetyl Hexapeptide-8 Skin & Repair Evidencia clínica No aprobado Cosmetic peptide with published human topical wrinkle studies; not a drug.
DSIP Delta Sleep-Inducing Peptide Sleep Evidencia clínica No aprobado Small human sleep/pain pilot trials with mixed results; never approved.
Epitalon Epithalon Longevity Evidencia clínica No aprobado Russian human clinical observations (Khavinson); no Western approval.
Thymosin Beta-4 TB4 Healing & Recovery Evidencia clínica No aprobado Full-length Tβ4 (RGN-259) tested in Phase 2/3 (dry eye/keratopathy); not approved.
CJC-1295 DAC Growth Hormone Evidencia clínica No aprobado Long-acting GHRH analog reached Phase 1/2 (ConjuChem); discontinued.
Follistatin 344 Growth Factor Evidencia clínica No aprobado AAV1-FS344 follistatin gene therapy reached Phase 1/2a; not commercial.
GHRP-6 Growth Hormone Evidencia clínica No aprobado GH-releasing hexapeptide studied in humans for GH secretion; not approved.
Kisspeptin Hormonal Evidencia clínica No aprobado Reproductive-hormone peptide studied in many human trials; not approved.
LL-37 Immune Evidencia clínica No aprobado Human cathelicidin investigated in early human wound/ulcer studies; not approved.
Matrixyl Palmitoyl Pentapeptide-4 Skin & Repair Evidencia clínica No aprobado Cosmetic anti-aging peptide with published human skin studies; not a drug.
Cagrilintide GLP-1 / Metabolic Evidencia clínica No aprobado Novo amylin analog in Phase 3 (CagriSema); not yet approved.
Tesofensine Metabolic Evidencia clínica No aprobado Triple monoamine reuptake inhibitor in Phase 3 for obesity; not approved.
Retatrutide 12mg LY3437943 GLP-1 / Metabolic Evidencia clínica No aprobado Same investigational molecule (12mg dose), Phase 3; not approved.
Hexarelin Growth Hormone Evidencia clínica No aprobado Same molecule as Examorelin; Phase 2, never marketed.
Survodutide BI 456906 GLP-1 / Metabolic Evidencia clínica No aprobado GLP-1/glucagon dual agonist in Phase 3 (obesity, MASH); FDA Breakthrough, not approved.
Adipotide FTPP Metabolic Evidencia clínica No aprobado Reached a Phase 1 oncology trial, terminated for nephrotoxicity.
Copper Tripeptide-1 GHK-Cu variant Skin & Repair Evidencia clínica No aprobado GHK-Cu has human topical wound/skin studies; cosmetic ingredient, not a drug.
ACE-031 Growth Factor Evidencia clínica No aprobado Myostatin trap reached randomized Phase 2 (DMD), halted 2011 for safety.
Larazotide Gastrointestinal Evidencia clínica No aprobado Zonulin antagonist completed Phase 3 (celiac); failed endpoint, not approved.
ARA-290 Cibinetide Healing & Recovery Evidencia clínica No aprobado EPO-derived peptide, Phase 2 in sarcoidosis neuropathy; no marketing approval.
Follistatin 315 Growth Factor Evidencia clínica No aprobado Delivered via AAV1-FS344 gene therapy in Phase 1/2a muscular dystrophy trials.
GHRP-1 Growth Hormone Evidencia clínica No aprobado Synthetic GH secretagogue tested in human GH-release studies; never approved.
Examorelin Hexarelin Growth Hormone Evidencia clínica No aprobado Hexarelin; reached Phase 2 (GHD, heart failure) but never marketed.
Vesugen Bioregulator Evidencia clínica No aprobado Khavinson vascular tripeptide with small non-controlled Russian human studies.
Vilon Bioregulator Evidencia clínica No aprobado Khavinson Lys-Glu dipeptide with small Russian immunogerontology human studies.
FGL FG Loop peptide Cognitive Evidencia clínica No aprobado NCAM-mimetic completed a Phase 1 intranasal safety study; not approved.
Testagen Bioregulator Evidencia clínica No aprobado Khavinson testis bioregulator with one small unreplicated Russian human study.
TB-500 Thymosin Beta-4 fragment Healing & Recovery Preclínico No aprobado Synthetic Tβ4 fragment with animal/in-vitro data only; no human trials of the fragment.
MOTS-c Metabolic Preclínico No aprobado Mitochondrial-derived peptide with extensive preclinical data; no controlled human therapeutic trials.
SLU-PP-332 Metabolic Preclínico No aprobado Pan-ERR agonist exercise-mimetic studied in mice/in-vitro only.
KPV Lysine-Proline-Valine Anti-inflammatory Preclínico No aprobado Anti-inflammatory α-MSH fragment with animal/in-vitro evidence only.
5-Amino-1MQ Metabolic Preclínico No aprobado NNMT inhibitor — mouse/in-vitro obesity data only; no human trials.
IGF-1 LR3 Growth Factor Preclínico No aprobado Long-acting IGF-1 analog research reagent; no human trials.
CJC-1295 (no DAC) Mod GRF 1-29 Growth Hormone Preclínico No aprobado Short-acting GHRH analog; no dedicated published human trials.
HGH Fragment 176-191 AOD precursor Metabolic Preclínico No aprobado Unmodified fragment has no human trials; only the modified AOD-9604 was tested in humans.
MGF Mechano Growth Factor Growth Factor Preclínico No aprobado IGF-1 splice variant with animal/in-vitro evidence only.
FOXO4-DRI Longevity Preclínico No aprobado Senolytic peptide studied in cell-culture and mice only.
Dihexa Cognitive Preclínico No aprobado Angiotensin-IV-derived cognitive peptide; animal/in-vitro only.
N-Acetyl Semax NA-Semax Cognitive Preclínico No aprobado Acetylated research analog of Semax; the analog itself lacks human trials.
PEG-MGF Growth Factor Preclínico No aprobado Pegylated IGF-1 splice variant; no published human trials.
PNC-27 Other Preclínico No aprobado p53-derived anti-cancer peptide tested in cell lines/animals only.
Humanin Longevity Preclínico No aprobado Studied in vitro/animals + observational plasma data; no interventional human trial.
IGF-1 DES DES(1-3) IGF-1 Growth Factor Preclínico No aprobado Truncated IGF-1 analog used in preclinical research only.
GDF-11 Longevity Preclínico No aprobado Animal/in-vitro therapeutic studies + observational biomarker data; no interventional human trials.
N-Acetyl Selank NA-Selank Cognitive Preclínico No aprobado Stabilized research analog of Selank; the analog itself lacks human trials.
Ovagen Bioregulator Preclínico No aprobado Khavinson tripeptide (supplement); animal/in-vitro, no controlled human trials.
Cortagen Bioregulator Preclínico No aprobado Khavinson cortex bioregulator (supplement); preclinical only.
P21 P021 Cognitive Preclínico No aprobado CNTF-mimetic neurogenic peptide with animal/in-vitro data only.
Pinealon Bioregulator Preclínico No aprobado Khavinson tripeptide (supplement); in-vitro/rodent data only.
Prostamax Bioregulator Preclínico No aprobado Khavinson tetrapeptide studied in rat/in-vitro models; no drug approval.
B7-33 Other Preclínico No aprobado Relaxin mimetic with rodent/in-vitro anti-fibrotic data only.
Livagen Bioregulator Preclínico No aprobado Russian bioregulator; small preclinical/cell-culture studies only.
Chonluten Bioregulator Preclínico No aprobado Khavinson respiratory tripeptide (supplement); preclinical/in-vitro only.
LL-37 (KR-12) KR-12 Immune Preclínico No aprobado Minimal antimicrobial fragment studied in vitro/animal only.
Cardiogen Bioregulator Preclínico No aprobado Khavinson cardiac bioregulator (supplement); preclinical only.
Bronchogen Bioregulator Preclínico No aprobado Khavinson bioregulator (supplement); Russian preclinical/in-vitro only.
Pancragen Bioregulator Preclínico No aprobado Khavinson tetrapeptide studied in animal/primate/in-vitro; no rigorous human trials.
ZP-3022 GLP-1 / Metabolic Preclínico No aprobado GLP-1/gastrin dual agonist studied in db/db mice & ZDF rats; no human trials.
SERP-2 Immune Preclínico No aprobado Myxoma-virus serpin studied in rodent models / human cell lines in vitro.
AHK-Cu Acetyl Tripeptide Copper, AHK Copper Skin & Repair Preclínico No aprobado —
Cartalax AED, Ala-Glu-Asp Bioregulator Preclínico No aprobado —
Crystagen EDP, Glu-Asp-Pro Immune Preclínico No aprobado —
Dermorphin Other Preclínico No aprobado —
GDF-8 Myostatin Growth Factor Preclínico No aprobado —
Orexin A Hypocretin-1 Sleep Preclínico No aprobado —
Orexin B Hypocretin-2 Sleep Preclínico No aprobado —
PE-22-28 Spadin analog Cognitive Preclínico No aprobado —
Lipo-C Metabolic Sin evidencia aún No aprobado Compounded MIC (methionine-inositol-choline) mix; no controlled efficacy studies of the formulation.

El estado de aprobación refleja registros regulatorios públicos en la última revisión y puede cambiar. La inclusión es informativa, no un respaldo; la mayoría de los compuestos son solo para uso en investigación de laboratorio y no están aprobados para uso humano.